This "This Week in Virology" episode features an in-depth interview with Stanley Platkin, a distinguished emeritus professor and vaccinologist. Platkin shares reflections on his extensive career, from early inspirations to his pivotal work in developing vaccines for polio, rubella (including the RA27/3 vaccine and WI-38 cell controversy), cytomegalovirus, and rabies. He recounts experiences at the CDC, Wistar Institute under Hilary Koprowski, and Pasteur Mérieux. The discussion delves into the historical context of vaccine development, the comparative efficacy of early polio vaccines, and the global efforts toward rubella eradication. Platkin also provides a critical analysis of contemporary public health challenges, including the rise of anti-vaccine sentiment, the erosion of public health infrastructure, the importance of science education and critical thinking, and the future landscape of vaccine research, utilization, and novel delivery methods.
A Conversation with Stanley Platkin: A Lifetime in Vaccinology
0:00 - Early Life & Inspiration: Stanley Platkin, an emeritus vaccinologist, reflects on his New York City upbringing, specialized science education at Bronx High School of Science, and how books like "Aerosmith" and "Microbe Hunters" ignited his passion for scientific research.
0:44 - Medical Training & Research Ambition: Despite an initial desire for research, he pursued medical school, supported by state scholarships, completing an internship and residency focused on learning from early vaccine researchers.
12:05 - CDC & Polio Vaccine Development: His stint with the CDC's Epidemic Intelligence Service led him to Hilary Koprowski's lab at the Wistar Institute, where he worked on attenuating polio viruses for a competing oral vaccine and conducted fieldwork in the Belgian Congo.
18:50 - Evolving Polio Vaccine Strategy: Platkin discusses the genetic instability of early oral polio vaccines (OPV). He advocates for a current shift from OPV to inactivated polio vaccine (IPV) due to eradication progress and the risk of vaccine-associated paralytic polio, criticizing existing WHO strategies.
24:45 - Rubella Vaccine Pioneer: Witnessed a rubella epidemic in the 1960s, which inspired his work on a vaccine. He cultivated rubella virus and became a crucial diagnostic resource during the US outbreak, highlighting the severe impact of congenital rubella syndrome.
32:04 - RA27/3 Rubella Vaccine & WI-38 Cells: Developed the highly effective RA27/3 rubella vaccine using the WI-38 human diploid cell strain, a decision that sparked controversy but proved safe and gained widespread acceptance, including by the Catholic Church.
41:50 - Rubella Eradication & Anti-Vaccine Backlash: Rubella is largely eliminated in many parts of the world. Platkin expresses dismay over the anti-MMR vaccine movement, linking it to declining scientific literacy and distrust of experts, warning that vaccine research leadership might shift globally.
43:50 - Persistent CMV Vaccine Dream: His long-standing goal is a cytomegalovirus (CMV) vaccine. Despite early success with an attenuated strain for transplant patients, concerns about live vaccines led to diverse research paths, including current mRNA trials, though the complex biology makes 100% protection challenging.
52:25 - Rabies Vaccine Success: Contributed to the development and clinical testing of an inactivated rabies vaccine at Wistar. This led to a highly effective vaccine that significantly reduced treatment doses. He explains that its post-exposure efficacy is due to the virus's slow progression to the brain.
59:00 - West Nile Virus & Public Health Communication: Describes West Nile Virus as an "American disease," urging renaming and increased public health efforts. He critiques the CDC's public outreach, linking its challenges to broader political issues and the need for better market appeal for a vaccine.
1:05:00 - Crisis in US Public Health & Education: Expresses profound concern over the "destruction of the public health apparatus" and the surge in anti-vaccine sentiment in the US. He calls for enhanced science and ethics education from grade school to foster critical thinking and combat misinformation.
1:11:00 - Industry Insights from Pasteur Mérieux: Spent seven years leading vaccine development at Pasteur Mérieux in Paris, observing both the efficiency of industry resources and the constraints of profit motives and internal competition.
1:17:50 - Personal Pursuit & Life Lessons: Fulfilled a lifelong dream of flying his own plane, appreciating the unique experience of flight, but eventually stopped due to age and reflex concerns, emphasizing the importance of recognizing one's limits.
1:20:30 - Countering Misinformation (Hepatitis B, Aluminum): Directly challenges RFK Jr.'s anti-vaccine claims, advocating for universal neonatal Hepatitis B vaccination for lifelong protection and affirming the safety of aluminum adjuvants based on scientific evidence, while condemning "junk science."
1:25:50 - Prediction of Disease Resurgence: Foresees the return of preventable diseases to the US as vaccination rates decline, potentially making the US a "control group" for future studies. Agrees that widespread illness and deaths might be the only way to shift public opinion.
1:33:50 - Lessons from Lyme Vaccine Failure: Recounts how public agitation, despite mild side effects, led to the withdrawal of a licensed Lyme vaccine in the 1990s, hoping that a new vaccine will avoid a similar fate.
1:37:00 - Future of Vaccinology: Utilization & Delivery: While vaccine development technology is advanced, the main challenge is now utilization and effective delivery. He highlights the potential of novel methods (e.g., dental floss vaccines) and the critical need to understand mucosal immunity for diseases like HIV.
1:43:50 - Enduring Research Interests: His primary interests remain completing a CMV vaccine and advancing HIV vaccine research, particularly in inducing robust mucosal immunity through innovative prime-boost strategies.